The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity
We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was achieved for 10/15 (...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2014-11, Vol.18 (11), p.1319-1322 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1322 |
|---|---|
| container_issue | 11 |
| container_start_page | 1319 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 18 |
| creator | Click, E. S. Chirenda, J. Kibias, S. Menzies, H. J. Oeltmann, J. E. Sentle, C. Muribe, T. Lere, T. D. Makombe, R. Bamrah, S. Moore, B. K. Cain, K. P. |
| description | We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was
achieved for 10/15 (67%, 95%CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537, 95%CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data. |
| doi_str_mv | 10.5588/ijtld.13.0710 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1610762899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2014/00000018/00000011/art00011</ingid><sourcerecordid>1639996505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-c37eec59b5825e68c331be6a2fe554a2b3c824ab106d65dfce5af65b0d31ec423</originalsourceid><addsrcrecordid>eNqNksuLFDEQxhtR3HX16FVyEbz0mEenO-1BWNYnLAiynkN1uno2Q08y5rEy_vVmXqseBHNJkfzyVVW-qqrnjC6kVOq1XaV5XDCxoB2jD6pzppisu57ThyWmvKtFx_qz6kmMK0o5Y6x7XJ1xyftetc15tbm5RTLaaLxzaBIZMP1AdASIg2S9g5mkPGAwefbRRjKGvCQBS5jAGSQxhzvcEnAjSQEhrdEl4nMyfo3xTZEpz8rBZuNDys6m7dPq0QRzxGfH_aL69uH9zdWn-vrLx89Xl9e1kapNtREdopH9IBWX2CojBBuwBT6hlA3wQRjFGxgYbcdWjpNBCVMrBzoKhqbh4qJ6e9Dd5GGNoyl1BZj1Jtg1hK32YPXfN87e6qW_07IXTMiuCLw6CgT_PWNMel2-CecZHPocNWtF3_etpPI_UEa7lqu-L2h9QE3wMQac7itiVO8M1XtDNRN6Z2jhX_zZxj19crAAL48ARAPzFIotNv7mlFK06UTh3h0465alY9Arn0OxN2qbYZfxkJdT1mi6X0ydAqYhpH1QZL7-S8aclHZjt5s6fceUK495mTtabNSskUqPOEGek04Q9PKnjkX0F-2S3yg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1610762899</pqid></control><display><type>article</type><title>The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Click, E. S. ; Chirenda, J. ; Kibias, S. ; Menzies, H. J. ; Oeltmann, J. E. ; Sentle, C. ; Muribe, T. ; Lere, T. D. ; Makombe, R. ; Bamrah, S. ; Moore, B. K. ; Cain, K. P.</creator><creatorcontrib>Click, E. S. ; Chirenda, J. ; Kibias, S. ; Menzies, H. J. ; Oeltmann, J. E. ; Sentle, C. ; Muribe, T. ; Lere, T. D. ; Makombe, R. ; Bamrah, S. ; Moore, B. K. ; Cain, K. P.</creatorcontrib><description>We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was
achieved for 10/15 (67%, 95%CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537, 95%CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.13.0710</identifier><identifier>PMID: 25299864</identifier><language>eng</language><publisher>Paris: International Union Against Tuberculosis and Lung Disease</publisher><subject>Antitubercular Agents - pharmacology ; Bacterial diseases ; Biological and medical sciences ; Botswana ; Drug ; Female ; Follow-Up Studies ; Human bacterial diseases ; Humans ; Infectious diseases ; Isoniazid - pharmacology ; Male ; Medical sciences ; Mycobacterium ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Outcome ; Pneumology ; Registries ; Resistance ; Retrospective Studies ; Survey ; Treatment ; Treatment Outcome ; Tuberculosis and atypical mycobacterial infections ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - microbiology</subject><ispartof>The international journal of tuberculosis and lung disease, 2014-11, Vol.18 (11), p.1319-1322</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-c37eec59b5825e68c331be6a2fe554a2b3c824ab106d65dfce5af65b0d31ec423</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28880473$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25299864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Click, E. S.</creatorcontrib><creatorcontrib>Chirenda, J.</creatorcontrib><creatorcontrib>Kibias, S.</creatorcontrib><creatorcontrib>Menzies, H. J.</creatorcontrib><creatorcontrib>Oeltmann, J. E.</creatorcontrib><creatorcontrib>Sentle, C.</creatorcontrib><creatorcontrib>Muribe, T.</creatorcontrib><creatorcontrib>Lere, T. D.</creatorcontrib><creatorcontrib>Makombe, R.</creatorcontrib><creatorcontrib>Bamrah, S.</creatorcontrib><creatorcontrib>Moore, B. K.</creatorcontrib><creatorcontrib>Cain, K. P.</creatorcontrib><title>The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was
achieved for 10/15 (67%, 95%CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537, 95%CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data.</description><subject>Antitubercular Agents - pharmacology</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Botswana</subject><subject>Drug</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Isoniazid - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mycobacterium</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Outcome</subject><subject>Pneumology</subject><subject>Registries</subject><subject>Resistance</subject><subject>Retrospective Studies</subject><subject>Survey</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNksuLFDEQxhtR3HX16FVyEbz0mEenO-1BWNYnLAiynkN1uno2Q08y5rEy_vVmXqseBHNJkfzyVVW-qqrnjC6kVOq1XaV5XDCxoB2jD6pzppisu57ThyWmvKtFx_qz6kmMK0o5Y6x7XJ1xyftetc15tbm5RTLaaLxzaBIZMP1AdASIg2S9g5mkPGAwefbRRjKGvCQBS5jAGSQxhzvcEnAjSQEhrdEl4nMyfo3xTZEpz8rBZuNDys6m7dPq0QRzxGfH_aL69uH9zdWn-vrLx89Xl9e1kapNtREdopH9IBWX2CojBBuwBT6hlA3wQRjFGxgYbcdWjpNBCVMrBzoKhqbh4qJ6e9Dd5GGNoyl1BZj1Jtg1hK32YPXfN87e6qW_07IXTMiuCLw6CgT_PWNMel2-CecZHPocNWtF3_etpPI_UEa7lqu-L2h9QE3wMQac7itiVO8M1XtDNRN6Z2jhX_zZxj19crAAL48ARAPzFIotNv7mlFK06UTh3h0465alY9Arn0OxN2qbYZfxkJdT1mi6X0ydAqYhpH1QZL7-S8aclHZjt5s6fceUK495mTtabNSskUqPOEGek04Q9PKnjkX0F-2S3yg</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Click, E. S.</creator><creator>Chirenda, J.</creator><creator>Kibias, S.</creator><creator>Menzies, H. J.</creator><creator>Oeltmann, J. E.</creator><creator>Sentle, C.</creator><creator>Muribe, T.</creator><creator>Lere, T. D.</creator><creator>Makombe, R.</creator><creator>Bamrah, S.</creator><creator>Moore, B. K.</creator><creator>Cain, K. P.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>20141101</creationdate><title>The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity</title><author>Click, E. S. ; Chirenda, J. ; Kibias, S. ; Menzies, H. J. ; Oeltmann, J. E. ; Sentle, C. ; Muribe, T. ; Lere, T. D. ; Makombe, R. ; Bamrah, S. ; Moore, B. K. ; Cain, K. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-c37eec59b5825e68c331be6a2fe554a2b3c824ab106d65dfce5af65b0d31ec423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antitubercular Agents - pharmacology</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Botswana</topic><topic>Drug</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Isoniazid - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mycobacterium</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Outcome</topic><topic>Pneumology</topic><topic>Registries</topic><topic>Resistance</topic><topic>Retrospective Studies</topic><topic>Survey</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Click, E. S.</creatorcontrib><creatorcontrib>Chirenda, J.</creatorcontrib><creatorcontrib>Kibias, S.</creatorcontrib><creatorcontrib>Menzies, H. J.</creatorcontrib><creatorcontrib>Oeltmann, J. E.</creatorcontrib><creatorcontrib>Sentle, C.</creatorcontrib><creatorcontrib>Muribe, T.</creatorcontrib><creatorcontrib>Lere, T. D.</creatorcontrib><creatorcontrib>Makombe, R.</creatorcontrib><creatorcontrib>Bamrah, S.</creatorcontrib><creatorcontrib>Moore, B. K.</creatorcontrib><creatorcontrib>Cain, K. P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Click, E. S.</au><au>Chirenda, J.</au><au>Kibias, S.</au><au>Menzies, H. J.</au><au>Oeltmann, J. E.</au><au>Sentle, C.</au><au>Muribe, T.</au><au>Lere, T. D.</au><au>Makombe, R.</au><au>Bamrah, S.</au><au>Moore, B. K.</au><au>Cain, K. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>18</volume><issue>11</issue><spage>1319</spage><epage>1322</epage><pages>1319-1322</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was
achieved for 10/15 (67%, 95%CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537, 95%CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data.</abstract><cop>Paris</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>25299864</pmid><doi>10.5588/ijtld.13.0710</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2014-11, Vol.18 (11), p.1319-1322 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1610762899 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antitubercular Agents - pharmacology Bacterial diseases Biological and medical sciences Botswana Drug Female Follow-Up Studies Human bacterial diseases Humans Infectious diseases Isoniazid - pharmacology Male Medical sciences Mycobacterium Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Outcome Pneumology Registries Resistance Retrospective Studies Survey Treatment Treatment Outcome Tuberculosis and atypical mycobacterial infections Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology |
| title | The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T13%3A46%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20disconnect%20between%20a%20national%20tuberculosis%20drug%20resistance%20survey%20and%20treatment%20outcomes:%20a%20lost%20opportunity&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Click,%20E.%20S.&rft.date=2014-11-01&rft.volume=18&rft.issue=11&rft.spage=1319&rft.epage=1322&rft.pages=1319-1322&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.13.0710&rft_dat=%3Cproquest_cross%3E1639996505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1610762899&rft_id=info:pmid/25299864&rft_ingid=iuatld/ijtld/2014/00000018/00000011/art00011&rfr_iscdi=true |